Cardiovascular disease (CVD) is considered the number one killer disease in the world, underlining the importance of the application of more accurate diagnostic and therapeutic tools. Traditional screening procedures usually do not provide identifica...
BACKGROUND: Obesity is a disease with high heterogeneity. Both overall obesity and central obesity are associated with increased risks of having cardio-metabolic co-morbidities. This study is aimed to examine the cardio-metabolic characteristics and ...
The rising prevalence of cardiometabolic multimorbidity (CMM), characterized by the coexistence of two or more cardiometabolic disorders, poses a significant public health challenge in aging populations. While ambient air pollution is a recognized en...
Biomedical physics & engineering express
Oct 23, 2025
Cardiovascular disease (CVD) is a major cause of morbidity and mortality in diabetic populations. Early detection of cardiovascular risk in diabetes is crucial to reduce complications, particularly in resource-limited settings. This study aimed to de...
OBJECTIVE: This study investigated the relationship between estimated glucose disposal rate (eGDR), aging acceleration (AgeAccel), and mortality in adults diagnosed with cardiovascular-kidney-metabolic (CKM) stages 1 to 4.
During the past 75 years, advances in cardiovascular science and technology have significantly reduced morbidity and mortality. In 2012, Drs Nabel and Braunwald reviewed this progress in , highlighting the landmark innovations that contributed to the...
Cardiovascular diseases (CVDs) are the leading cause of death worldwide, and current predictors such as lipoprotein (a) [Lp(a)] and risk scores have limitations. Automated machine learning (AutoML) offers the potential to improve CVD risk prediction ...
Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have demonstrated strong efficacy in preventing symptomatic disease, but adverse cardiovascular side effects have been reported. This study investigated whether noninvasive...
BACKGROUND: It remains unclear whether certain individuals with type 2 diabetes (T2D) derive greater cardiovascular benefit from GLP-1 receptor agonists (GLP-1RAs). Here, we integrate individual-level data from cardiovascular outcome trials (CVOTs) a...
BACKGROUND: Cardiovascular disease remains the predominant cause of morbidity and mortality in individuals with type 2 diabetes mellitus (T2DM). Traditional risk models are limited in predictive accuracy. Pericoronary adipose tissue (PCAT), a novel i...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.